Starting around 2023, isolated case reports and pharmacovigilance database signals raised a concerning question about GLP-1 medications like semaglutide and liraglutide: could they be associated with an increased risk of suicidal thoughts or behavior? Both the FDA and the European Medicines Agency opened formal reviews. In January 2026, the FDA announced the conclusion of its review, and the result was the opposite of what the early case reports had suggested.
What the Larger Studies Found
Individual case reports, by design, can flag a possible concern but can't establish whether a drug actually causes it, since they don't have a comparison group. The FDA's review drew instead on larger, controlled data: a meta-analysis pooling 91 clinical trials involving more than 107,000 patients found no increased risk of suicidal thoughts or behavior associated with GLP-1 receptor agonist use. A separate retrospective study following more than 2.2 million users found no elevated risk of self-harm compared with patients using other diabetes medications. Additional published observational research reviewed by the agency did not support a causal relationship between these drugs and suicidal ideation.
What the FDA Did About It
Based on that review, the FDA requested the removal of suicidal ideation and behavior warnings from the labels of three weight-management GLP-1 drugs, Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), stating plainly that it found no increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonist use. Part of the agency's stated rationale was consistency: the same active ingredients, when prescribed for type 2 diabetes rather than weight management, never carried this warning in the first place, an inconsistency the labeling change was intended to resolve.
What This Does and Doesn't Mean
A finding of "no increased risk in the aggregate data reviewed" is not the same as "impossible for any individual to experience mood changes while using these drugs." Rapid weight loss, changes in appetite-related brain signaling, and the broader life changes that come with significant weight change can all affect mood in ways worth monitoring on an individual level, separate from the specific suicidality question the FDA's review addressed. People with a personal or family history of depression, anxiety, or other mental health conditions are a group where this kind of individual monitoring is particularly relevant, even though the aggregate data didn't show an elevated suicidality signal for the population as a whole.
The Bottom Line
The best available evidence, drawn from tens of thousands of trial participants and millions of real-world users, does not support a causal link between GLP-1 medications and increased suicide risk, which is why U.S. regulators moved to remove the warning rather than strengthen it. That said, any new or worsening mood symptoms after starting a GLP-1 medication are worth reporting to a prescriber directly and promptly, both for your own care and because ongoing pharmacovigilance monitoring depends on those individual reports being made.